Omnix Medical
Founded in 2015, Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Their innovative technology focuses on natural antimicrobial peptides, engineered for therapeutic use, targeting severe hospital-acquired infections and addressing the urgent threat posed by multidrug-resistant pathogens. The company is building a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections associated with multi-drug resistances.
Omnix Medical
High-Tech Village Givat Ram Campus, Jerusalem Israel
Patents
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
2020-08-18 • US-10745452-B2
View Details
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
2020-08-18 • US-10745452-B2
View DetailsWhat We Do
Antimicrobial Peptides Development
Development of novel antimicrobial peptides designed to effectively target and kill drug-resistant bacteria, particularly those causing hospital-acquired infections.
Regulatory Support
Assistance in navigating the regulatory pathways for drug approval, including obtaining Qualified Infectious Disease Product (QIDP) designation from the FDA.
A first-in-class drug targeting multidrug-resistant bacteria, utilizing a unique mechanism of action that avoids resistance development. OMN6 is currently being evaluated in a Phase-I trial in The Netherlands, targeting Gram-negative bacteria, particularly Acinetobacter baumannii.
OMN-51
A new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa, which causes recurrent infections in patients with Cystic Fibrosis.
OMN-71
A new antimicrobial peptide (AMP) targeting gastrointestinal tract infections involving Salmonella and bacteria involved in skin infections, particularly those resistant to current treatments.
Antimicrobial Peptides Development
Development of novel antimicrobial peptides designed to effectively target and kill drug-resistant bacteria, particularly those causing hospital-acquired infections.
Regulatory Support
Assistance in navigating the regulatory pathways for drug approval, including obtaining Qualified Infectious Disease Product (QIDP) designation from the FDA.
A first-in-class drug targeting multidrug-resistant bacteria, utilizing a unique mechanism of action that avoids resistance development. OMN6 is currently being evaluated in a Phase-I trial in The Netherlands, targeting Gram-negative bacteria, particularly Acinetobacter baumannii.
OMN-51
A new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa, which causes recurrent infections in patients with Cystic Fibrosis.
OMN-71
A new antimicrobial peptide (AMP) targeting gastrointestinal tract infections involving Salmonella and bacteria involved in skin infections, particularly those resistant to current treatments.
Infectious Diseases
Drugs
Routes of Administration
Key People
News & Updates
Results from the first-in-human study of OMN6, a novel antimicrobial peptide for Acinetobacter baumannii, conducted in healthy volunteers.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA granted fast-track designation for OMN6, highlighting the urgent need for novel antimicrobials against Gram-negative bacteria.
Announcement of FDA approval for a Phase II trial of OMN6, aimed at treating life-threatening infections caused by Acinetobacter baumannii.
An overview of the innovative technology behind Omnix Medical's antibiotic development, focusing on antimicrobial peptides.
The Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of multidrug-resistant bacteria.
Results from the first-in-human study of OMN6, a novel antimicrobial peptide for Acinetobacter baumannii, conducted in healthy volunteers.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA granted fast-track designation for OMN6, highlighting the urgent need for novel antimicrobials against Gram-negative bacteria.
Announcement of FDA approval for a Phase II trial of OMN6, aimed at treating life-threatening infections caused by Acinetobacter baumannii.
An overview of the innovative technology behind Omnix Medical's antibiotic development, focusing on antimicrobial peptides.
The Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of multidrug-resistant bacteria.